Map claims to evidence strength, expert review status, uncertainty, and revision history. Confidence states: preliminary → evidence-backed → expert-reviewed → revised.
| Claim | Evidence | Expert status | Uncertainty | Confidence | Sources | Share |
|---|---|---|---|---|---|---|
| Potency assay ambiguity remains one of the central bottlenecks in therapeutic EV development. Without a mechanism-linked potency assay, batch release and comparability are weakened. | High | pending | Medium | evidence backed | ||
| Local and topical EV applications may be more practical than broad systemic regenerative EV therapy. Delivery route and exposure drive CMC burden and clinical feasibility. | Medium | pending | Low-medium | evidence backed | ||
| Engineered EV delivery platforms must demonstrate clear advantage over LNP, AAV, and other established delivery modalities. Capital and development timelines require differentiated delivery economics and biodistribution. | High | pending | Medium | preliminary | ||
| Unapproved exosome clinic products carry significant regulatory and patient-safety risk and are not a credible venture pathway. Therapeutic claims require IND-enabled GMP development, not cash-pay clinic economics. | High | documented | Low | evidence backed | ||
| EV manufacturing is improving but remains a CMC-heavy, non-commodity process—not plug-and-play biologics manufacturing. COGS, facility design, and comparability drive venture capital intensity and timeline risk. | High | pending | Medium | evidence backed | ||
| Isolation and purification method largely defines the therapeutic EV product identity. Process changes without comparability data are regulatory and investment red flags. | High | pending | Low | evidence backed |
Engineered EV delivery platforms must demonstrate clear advantage over LNP, AAV, and other established delivery modalities.
Capital and development timelines require differentiated delivery economics and biodistribution.
Evox Therapeutics (2023). Evox progress on DeliverEX and ExoEdit platforms
Engineered exosome delivery for mRNA, RNAi, and gene editing; company claims vs LNP at equal dose in preclinical work.
Open source →Supports claims: engineered_ev_vs_lnp
Smith et al. (2023). Robust mRNA loading and delivery by engineered extracellular vesicles
Preclinical comparison of EV vs LNP mRNA delivery; not peer-reviewed—verify independently.
Open source →Supports claims: engineered_ev_vs_lnp
Example only: reviewers often flag potency assays that measure generic immunomodulation without linkage to intended MOA in the target indication.
No revisions yet. Revisions will appear after expert feedback updates claim text.